Table 1. Results of G-CAN member survey on CPPD.
The following CPPD domains were addressed: CP: clinical phenotyping, D Detection & Diagnosis: P: pathogenesis, SM: stratified medicine, O: outcomes; T: treatment.
| Research priority (domain1) | % rating ≥ important |
|---|---|
| Identify and test new approaches for preventing, limiting and/or reversing CPPD (T) | 96% |
| Develop improved analytic techniques for detection of CPP crystals in tissues, including pragmatic point-of-care systems (D) | 92% |
| Better definition of the mechanisms by which CPPD develops in joints with and without OA (P)2 | 88% |
| Develop advanced imaging modalities for improved detection of intra-articular CPPD (D) | 85% |
| Evaluate efficacy and safety of colchicine, corticosteroids, disease-modifying anti-rheumatic drugs, and cytokine antagonists in acute and chronic CPP crystal arthritis (T) | 85% |
| Improve phenotyping of inflammatory and non-inflammatory arthropathies associated with CPPD (CP)2 | 84% |
| Identification of basic mechanisms and other factors causing symptomatic acute arthritis in CPPD, including its’ triggers (P) | 81% |
| Identify people likely to benefit from reducing CPP crystal deposition (SM) | 81% |
| Define precise clinical relationship between primary CPPD with non-inflammatory arthritis, and OA with CPPD (CP) | 77% |
| Better define the impact of CPPD on the outcome of OA (O) | 77% |
| Identify mechanisms causing chronic arthritis and damage in CPPD (P)2 | 76% |
| Understand the natural history of CPPD, including changes in clinical phenotype and transition to symptomatic CPPD (O) | 73% |
| Identify patients who would benefit from reducing CPP crystal-induced inflammation (SM) | 69% |
| Identify genetic and epigenetic factors in idiopathic CPP crystal arthritis (P) | 62% |
| Identification of risk factors for CPPD (P) | 62% |
| Identify biomarkers of development of CPPD (SM)2 | 52% |
| Identify people with CPPD for whom screening for metabolic diseases is appropriate (SM)3 | 48% |
| Evaluate effect of CPPD on outcomes of arthroplasty (O)3 | 39% |
1
Domains assessed: CP: clinical phenotyping, D Detection & Diagnosis: P: pathogenesis, SM: stratified medicine, O: outcomes; T: treatment;
2
25 completed responses;
3
23 completed responses.